KALA - カラ・ファ―マシュ―ティカルズ (Kala Pharmaceuticals Inc.) カラ・ファ―マシュ―ティカルズ

 KALAのチャート


 KALAの企業情報

symbol KALA
会社名 Kala Pharmaceuticals Inc (カラ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 カラ・ファーマスーティカルズ(Kala Pharmaceuticals Inc.)はナノ粒子ベースの粘膜浸透性粒子(MPP)技術による治療薬の開発と商品化に重点を置くバイオ医薬品会社である。同社の最初の焦点は眼疾患の治療にある。同社の製品候補には、KPI-121 1%、KPI-121 0.25%およびMPP rTKIプログラムが含まれる。同社はKPI-121 1%について2つの第III相臨床試験を完了する。KPI-121 0.25%はドライアイ疾患の徴候および症状の一時的軽減用製品候補である。KPI-121 1%は手術後の炎症および疼痛処置用の1日2回の製品候補である。MPP rTKIプログラムは毎月の間隔で患者の眼に直接注入する網膜疾患治療法である。   カラ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。眼科疾患を治療するナノ粒子ベ―ス「Mucus Penetraiting Particles」(MPP)技術を用いた医薬品の開発・商業化に従事する。ナノ粒子はサイズが選択可能で、粘液による薬物粒子の移動性を高める。眼科手術後の炎症、ドライアイや網膜疾患の治療に使われる。本社はマサチュ―セッツ州ウォルサム。   Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.
本社所在地 100 Beaver Street Suite 201 Waltham MA 02453 USA
代表者氏名 Mark T. Iwicki Mark T. Iwicki
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 781-996-5252
設立年月日 39965
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 37人
url www.kalarx.com
nasdaq_url https://www.nasdaq.com/symbol/kala
adr_tso
EBITDA EBITDA(百万ドル) -45.82500
終値(lastsale) 8.31
時価総額(marketcap) 204481460.94
時価総額 時価総額(百万ドル) 306.72840
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 235.29040
当期純利益 当期純利益(百万ドル) -47.38200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Kala Pharmaceuticals Inc revenues was not reported. Net loss increased 25% to $25.9M. Higher net loss reflects General and administrative - Balancing v increase from $2.4M to $9.9M (expense) Stock-Based Compensation increase from $697K to $2.8M (expense) Stock-Based Compensation increase from $392K to $1.4M (expense).

 KALAのテクニカル分析


 KALAのニュース

   Kala Pharmaceuticals (KALA) Investor Presentation - Slideshow  2021/09/16 19:27:10 Seeking Alpha
   Reeling stocks: Kala Pharmaceuticals, Inc. (NASDAQ:KALA -0.91%), Senmiao Technology Limited (NASDAQ:AIHS -3.12%)  2021/09/08 22:43:04 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Reeling stocks: Kala Pharmaceuticals, Inc. (NASDAQ:KALA -0.91%), Senmiao Technology Limited (NASDAQ:AIHS -3.12%) appeared first on Stocks Equity .
   Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021  2021/09/07 12:00:00 Intrado Digital Media
WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in September 2021:
   Breathtaking stocks: Yamana Gold Inc. (NYSE:AUY 3.28%), Kala Pharmaceuticals, Inc. (NASDAQ:KALA -6.59%)  2021/09/06 22:20:03 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Breathtaking stocks: Yamana Gold Inc. (NYSE:AUY 3.28%), Kala Pharmaceuticals, Inc. (NASDAQ:KALA -6.59%) appeared first on Stocks Equity .
   Thinking about buying stock in Marqeta, Lexicon Pharmaceuticals, Kala Pharmaceuticals, Owlet, or New Oriental Education?  2021/08/30 13:31:00 Benzinga
NEW YORK , Aug. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MQ, LXRX, KALA, OWLT, and EDU.
   Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2021 Results - Earnings Call Transcript  2021/08/05 18:48:05 Seeking Alpha
   Kala Pharmaceuticals EPS misses by $0.13, misses on revenue  2021/08/05 11:02:57 Seeking Alpha
   Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update  2021/08/05 11:00:00 Intrado Digital Media
-- EYSUVIS Prescriptions Increased by 93% Compared to First Quarter of 2021 -- -- Further Expanded Commercial Coverage for EYSUVIS to More Than 96 Million Lives -- -- Achieved $3.1 Million in Net Revenue in Second Quarter of 2021 -- -- Conference Call and Webcast at 8:00 a.m. ET -- WATERTOWN, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
   Kala Pharmaceuticals Inc Shares Fall 1.5% Below Previous 52-Week Low - Market Mover  2021/08/05 08:08:52 Kwhen Finance
Kala Pharmaceuticals Inc (KALA) shares closed 1.5% lower than its previous 52 week low, giving the company a market cap of $223M. The stock is currently down 49.1% year-to-date, down 62.8% over the past 12 months, and down 81.3% over the past five years. This week, the Dow Jones Industrial Average rose 0.1%, and the S&P 500 rose 0.5%. Trading Activity Trading volume this week was 38.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 438.6% The company's stock price performance over the past 12 months lags the peer average by 143.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Eye-catching Hot Stock: AT&T Inc. (NYSE:T), Kala Pharmaceuticals, Inc. (NASDAQ:KALA)  2021/08/04 21:55:37 Stock Equity
AT&T Inc. (NYSE:T) with the stream of -1.10% also noticed, India Kala Pharmaceuticals, Inc. (NASDAQ:KALA) encountered a rapid change of -2.90% in the last hour of Wednesdays trading session. AT&T The post Eye-catching Hot Stock: AT&T Inc. (NYSE:T), Kala Pharmaceuticals, Inc. (NASDAQ:KALA) appeared first on Stocks Equity .
   Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Wire  2021/06/24 19:40:44 Business Wire
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
   Kala Pharmaceuticals Announces EYSUVIS Now Covered by OptumRx  2021/06/03 11:00:00 Wallstreet:Online
Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies,
   Are Institutions Heavily Invested In Kala Pharmaceuticals, Inc.''s (NASDAQ-KALA) Shares?  2021/06/03 00:32:24 Simply Wall St
Are Institutions Heavily Invested In Kala Pharmaceuticals, Inc.''s (NASDAQ:KALA) Shares? Simply Wall St
   Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx  2021/06/03 00:00:00 BioSpace
Kala Pharmaceuticals, Inc., today announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021.
   Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference  2021/05/27 00:00:00 BioSpace
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2021 Virtual Healthcare Conference. Management is scheduled to participate in a fireside chat on Thursday, June 3, 2021 at 10:00 am ET.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カラ・ファ―マシュ―ティカルズ KALA Kala Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)